Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Familial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency resulting in fasting chylomicronemia and severe hypertriglyceridemia. Inhibition of diacylglycerol acyltransferase 1 (DGAT1), which mediates chylomicron triglyceride (TG) synthesis, is an attractive strategy to reduce TG levels in FCS. In this study we assessed the safety, tolerability and TG-lowering efficacy of the DGAT1 inhibitor pradigastat in patients with FCS. METHODS: Six FCS patients were enrolled in an open-label clinical study. Following a 1-week very low fat diet run-in period patients underwent baseline lipid assessments, including a low fat meal tolerance test. Patients then underwent three consecutive 21 day treatment periods (pradigastat at 20, 40 & 10 mg, respectively). Treatment periods were separated by washout periods of ≥4 weeks. Fasting TG levels were assessed weekly through the treatment periods. Postprandial TGs, ApoB48 and lipoprotein lipid content were also monitored. RESULTS: Following once daily oral dosing, steady-state exposure was reached by Day 14. There was an approximately dose proportional increase in pradigastat exposure at studied doses. Pradigastat was associated with a 41% (20 mg) and 70% (40 mg) reduction in fasting triglyceride over 21 days of treatment. The reduction in fasting TG was almost entirely accounted for by a reduction in chylomicron TG. Pradigastat treatment also led to substantial reductions in postprandial TG as well as apo48 (both fasting and postprandial). Pradigastat was safe and well tolerated, with only mild, transient gastrointestinal adverse events. CONCLUSION: The novel DGAT1 inhibitor pradigastat substantially reduces plasma TG levels in FCS patients, and may be a promising new treatment for this orphan disease. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01146522 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In six FCS patients, pradigastat reduced fasting TG by 70%.89”
From Clinical review on triglycerides (2020) · cites this paper as [89]
Experimental — accuracy not yet measuredIn the citing paper
“The prevalence of HeFH in the population is estimated to be 1/ 200-250, 361 translating to a total number of cases between 14 and 34 million worldwide [362,363].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [362]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404 · cited 2×
“LPL gene replacement therapy has recently been approved in Europe, although its use is currently restricted to the most severely affected patients with FCS due to an LPL gene defect and recurrent pancreatitis [8,9].”
Self-citationMutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia
Surendran, R. P., Visser, M. E., Heemelaar, S., Wang, J., Peter, J., Defesche, J. C., Kuivenhoven, J. A., Hosseini, M., Péterfy, M., Kastelein, J. J. P., et al. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02516.x · Cited by 249 · cited 1×
“chylomicronemia), and severe hypertriglyceridemia [2,3].”
DGAT1 Is Not Essential for Intestinal Triacylglycerol Absorption or Chylomicron Synthesis
Buhman, K. K., Smith, S. J., Stone, S. J., Repa, J. J., Wong, J. S., Knapp, F. F., Burri, B. J., Hamilton, R. L., Abumrad, N. A., & Farese, R. V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202013200 · Cited by 242 · cited 2×
“DGAT1-deficient mice are protected from the typical post-meal spike in plasma TG levels, and have significantly decreased post meal levels of CMs [11].”
(2001) · Medical Entomology and Zoology · Cited by 227
Gene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178 · cited 1×
“LPL gene replacement therapy has recently been approved in Europe, although its use is currently restricted to the most severely affected patients with FCS due to an LPL gene defect and recurrent pancreatitis [8,9].”
Self-citationCarpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165 · cited 1×
“Recently adeno-associated virus type I LPL gene therapy was approved in Europe for the treatment of FCS in a subset of patients with recurrent pancreatitis [9,16].”
Self-citationGenetic bases of hypertriglyceridemic phenotypes
Johansen, C. T., & Hegele, R. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283471972 · Cited by 127 · cited 1×
“chylomicronemia), and severe hypertriglyceridemia [2,3].”
Chylomicronemia Syndrome in Diabetes Mellitus
Chait, A., Robertson, H. T., & Brunzell, J. D. (1981) · Diabetes Care · doi:10.2337/diacare.4.3.343 · Cited by 83 · cited 1×
“Discussion Plasma TG levels are difficult to control in FCS patients, and as a result these patients are at high risk of developing recurrent pancreatitis [1,15].”
Acylation of Acylglycerols by Acyl Coenzyme A:Diacylglycerol Acyltransferase 1 (DGAT1)
Cheng, D., Iqbal, J., Devenny, J. J., Chu, C.-H., Chen, L., Dong, J., Seethala, R., Keim, W. J., Azzara, A. V., Lawrence, R. M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800494200 · Cited by 81 · cited 1×
“Diacylglycerol acyltransferase-1 (DGAT1) catalyzes the final step in TG synthesis and is highly expressed in the small intestine enterocytes, where it plays a key role in absorption of dietary fat [10].”
Denison, H., Nilsson, C., Kujacic, M., Löfgren, L., Karlsson, C., Knutsson, M., & Eriksson, J. W. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12002 · Cited by 68 · cited 1×
“The very low fat diet recommended for FCS patients appears to improve the tolerability profile of DGAT1 inhibitors compared to other studies with higher dietary fat content [17].”
Research works printed but not linked: 1
- Upthagrove A, Einolf H, Hanna I, Bretz A, Wang L, Peng L: Disposition of pradigastat (LCQ908) in humans: in vivo and in vitro investigations. 2013
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“The risk of pancreatitis is clinically significant if TGs are >10 mmol/L (880 mg/dL), particularly when occurring in association with familial chylomicronaemia, and actions to prevent acute pancreatitis are mandatory.(381,382) Notably, HTG is the cause of 10% of all cases with pancreatitis, and patients can develop pa…”
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“In phase I/II trials, six familial chylomicronaemia syndrome patients showed a dosedependent reduction in TG of 41–70% over 21 days of treatment with only mild transient gastrointestinal adverse events in patients receiving dose-ranging pradigastat.(302) A trial from 106 participants with overweight or obesity receivi…”
BackgroundNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“Thoughmany subjects experience some gastrointestinal side effects, these were mild and tolerable (Meyers et al., 2015).”
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“In six FCS patients, pradigastat reduced fasting TG by 70%.(89) In obese patients with milder dyslipidaemia, pradigastat improved TG and other metabolic traits.”
Background
Metadata
- Authors
- Meyers, C. D., Tremblay, K., Amer, A., Chen, J., Jiang, L., & Gaudet, D.
- Affiliations
- Université de Montréal (CA)
- Corresponding author
- Meyers, Charles Daniel
- Venue
- Lipids in Health and Disease
- Published
- 2015-02-18
- Volume
- 14
- Issue
- 1
- Pages
- 8-8
- ISSN
- 1476-511X (ISSN-L)
- PMC
- PMC4337059
- OpenAlex
- W2130127759
- Cited by
- 110
- References
- 18
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 7 · 2020: 12 · 2019: 11 · 2018: 13 · 2017: 12 · 2016: 13 · 2015: 5
- FWCI
- 10.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Lipids in Health and Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- Clinical Trial Center, China Medical University Hospital
- Université de Montréal
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- DGAT1 inhibitors, familial chylomicronemia syndrome, lipoprotein lipase deficiency, hypertriglyceridemia, triglyceride-lowering therapy, apoB-48, postprandial triglycerides, drug safety and tolerability, rare diseases
- MeSH terms
- Acetates, Adult, Aged, Aminopyridines, Female, Humans, Hyperlipoproteinemia Type I, Male, Middle Aged, Triglycerides, Diacylglycerol O-Acyltransferase, Apolipoprotein B-48
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. https://app.cochat.ai/papers/10.1186/s12944-015-0006-5
- The paper
- Meyers, C. D., Tremblay, K., Amer, A., Chen, J., Jiang, L., & Gaudet, D. (2015). Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids in Health and Disease. https://doi.org/10.1186/s12944-015-0006-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.